Details of the Drug

General Information of Drug (ID: DMH5YQ3)

Drug Name
Sugemalimab
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Approved in China [1]
Extranodal NK/T-cell Lymphoma 2A90.6 Phase 3 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DDZ48Y
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
2 ClinicalTrials.gov (NCT05700448) A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL). U.S.National Institutes of Health.
3 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.